Purpose: To describe the data and analyses that led to the FDA approval of ofatumumab (Arzerra TM ) for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
Introduction:
CLL is a clonal disorder of B cells with a variable clinical course. Median survival is longer than 10 years 1 ; however, reported median survival is only two to three years for patients with high risk disease (Rai category III or IV or Binet stage 3) [1] . Reported survival in CLL patients whose disease is refractory to multiple drugs is shorter; in one report, median survival was 8 months in patients with CLL refractory to fludarabine and alemtuzumab [2] .
In the past decade, regular FDA approval for the treatment of patients with CLL has been based on a clinically meaningful prolongation of progression-free survival (PFS) accompanied by an acceptable safety profile, while accelerated approval has been granted based on durable overall response rates (ORR) in patients with CLL that has progressed following available therapy. In order to be considered for accelerated approval, a drug which shows an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit must treat a serious or life-threatening disease or condition and demonstrate an advantage over available therapy [3] . Additionally, the commercial manufacturer must commit to study the drug further to verify and characterize the predicted clinical benefit [3] .
Alemtuzumab received accelerated approval in 2001 and regular approval in 2007.
Accelerated approval was based on the results of three single-arm studies enrolling 149 patients with CLL and progressive disease following alkylating agents and fludarabine.
The rates of durable objective responses (ORR) in the three studies ranged from 21% to 33% [4] . Regular approval was based on superior PFS [HR 0.58 (95% CI 0.43, 0.77), p<0.0001 stratified log-rank test] in a randomized active-controlled study comparing alemtuzumab to chlorambucil in previously untreated patients with CLL [4] .
Alemtuzumab also demonstrated an improvement in ORR (83% vs. 55%) and complete response rates (24% vs. 2%) compared to chlorambucil [4] . to chlorambucil in previously untreated patients with CLL. In the study, bendamustine also demonstrated an improvement in ORR (59% vs. 26%) and complete response rates (8% vs. <1%) compared to chlorambucil [5] .
In addition to bendamustine and alemtuzumab, the following drugs are approved for the treatment of patients with CLL: fludarabine, cyclophosphamide, and chlorambucil.
These drugs were approved based on durable objective tumor responses prior to the codification of the accelerated approval regulations.
The Biologics License Application (BLA) for ofatumumab was submitted on January 30,
2009
. The application contained the interim results of a single-arm, fixed dose, multicenter trial (Hx-CD20-406) and the final results of a multicenter, sequential doseescalating cohort and activity estimating trial (Hx-CD20-402) which utilized a shorter treatment duration (four doses vs. twelve doses) than the primary efficacy study. Both trials enrolled adults with CLL who had relapsed following or were refractory to one or more standard treatments. This was supported by safety information from several trials enrolling 151 patients with follicular lymphoma or diffuse large B-cell lymphoma, 282 patients with rheumatoid arthritis or chronic obstructive pulmonary disease, and 28 patients with CLL who received ofatumumab in combination with chemotherapy. The primary efficacy trial utilized the highest dose and longest duration of ofatumumab in the clinical safety database.
Chemistry, Manufacturing, and Controls
Ofatumumab is an IgG1 kappa human monoclonal antibody with a molecular weight of approximately 149 kDa [6] . The antibody was generated via transgenic mouse and hybridoma technology and is produced in a recombinant murine cell line (NS0) using standard mammalian cell cultivation and purification technologies [6] . It is supplied as a sterile, colorless, preservative-free liquid concentrate at a concentration of 20 mg/mL in a 5 mL volume of solution for intravenous infusion in a 10 mL single use vial (100 mg/vial) [6] .
Nonclinical Pharmacology and Toxicology
Ofatumumab binds specifically to the CD20 molecule, which is expressed on normal B lymphocytes (pre-B-to mature B-lymphocyte) and on B-cell CLL tumor cells. The CD20 molecule is not shed from the cell surface and is not internalized following antibody binding [6] . The Fab domain of ofatumumab binds to the CD20 molecule and the Fc domain mediates immune effector functions to result in B-cell lysis in vitro [6] .
Possible mechanisms of action for ofatumumab include complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.
Non-clinical data submitted in support of the application included tissue binding studies in human and cynomolgus monkey tissue panels, evaluation of in vitro pharmacologic activity (receptor binding, lysis of CD20-expressing cells), and in vivo pharmacologic activity (anti-tumor activity in SCID mice bearing human tumor xenografts, characterization of B-cell depletion in treated monkeys), pharmacokinetic studies in cynomolgus monkeys, and subacute (4-week) and chronic (7-month) toxicology studies in cynomolgus monkeys. The major ofatumumab toxicities observed in nonclinical studies were extensions of its expected pharmacologic activity, i.e., the severe and prolonged depletion of B-lymphocytes both in the circulation and in the major lymphoid organs (follicular germ centers of the spleen, cortical lymph nodes, and Peyer's patches in the gastrointestinal tract). Other toxicities observed in the 7-month repeat-dose cynomolgus monkey toxicity study included sporadic, non-severe infusion reactions, hematologic changes including B-cell depletion, mild hemolytic anemia, and changes in neo-and recall antigen responses.
Clinical Pharmacology
Pharmacokinetic data were obtained from 146 patients with refractory CLL who received a 300-mg initial dose followed by 7 weekly and 4 monthly infusions of 2,000 mg [6] . The and 60% higher than after the 4 th infusion in Study Hx-CD20-402 [6] . The mean volume 6 of distribution at steady-state (V ss ) values ranged from 1.7 to 5.1 L [6] . Ofatumumab is eliminated through both a target-independent route and a B cell-mediated route [6] .
Ofatumumab exhibited dose-dependent clearance in the dose range of 100 to 2,000 mg [6] . Due to the depletion of B cells, the clearance of ofatumumab decreased substantially after subsequent infusions compared to the first infusion [6] . [6] . Gender did not influence ofatumumab pharmacokinetics after correcting for body weight differences. Although volume of distribution and clearance increased with body weight [6] , it did not explain intersubject variation for the clinical endpoint.
In patients with CLL refractory to fludarabine and alemtuzumab, the median decrease in circulating CD19-positive B cells was 91% (n = 50) with the 8 th infusion and 85%
(n = 32) with the 12 th infusion [6] . The time to recovery of lymphocytes, including CD19-positive B cells, to normal levels could not be determined using the data submitted to the BLA.
Clinical Studies

Materials and Methods
The major efficacy (Hx-CD20-406) and dose-finding (Hx-CD20-402) trials were conducted by Genmab A/S. Study Hx-CD20-402 was a multicenter, sequential doseescalating and activity-estimating trial that enrolled a total of 33 patients with previously treated CLL. There were three dose cohorts studied with an expansion of the highest dose cohort to further evaluate anti-tumor activity. The treatment regimen was limited to 4 weekly doses as follows: level 1 received 100 mg week 1 and 500 mg weeks 2-4 (n=3), Hx-CD20-406 was an open-label, multicenter, international, single-arm, fixed dose trial.
Eligibility was limited to patients 18 years of age or older, ECOG PS 0-2, with CLL requiring treatment as defined in the NCI Working Group (1996 NCIWG) guidelines [7] .
All patients were required to be refractory to fludarabine (minimum of two cycles) and to be refractory to alemtuzumab [double refractory ( Protocol specified monitoring included assessment of CLL status at baseline, every four weeks until week 28, then every three months until month 24. CLL disease status assessments consisted of measurements of lymph nodes, liver, and spleen by physical examination; complete blood counts including hemoglobin, platelet, neutrophil, and lymphocyte counts; and queries for constitutional symptoms. Bone marrow aspiration and biopsy and CT scan of the neck, chest, abdomen, and pelvis were obtained at baseline and for confirmation of a complete response. All adverse events were collected up to 24 months following study entry; serious adverse events, resulting in hospitalization or death, and peripheral B-lymphocyte counts were collected for 48 months or until initiation of alternative anti-CLL therapy, whichever occurred earlier.
The primary endpoint was objective response rate (ORR), based on the 1996 NCIWG criteria for response, occurring at any time between the first dose of ofatumumab through week 24, as determined by an Independent Endpoints Review Committee (IRC). The IRC was composed of five independent board certified oncologists or hematologists experienced with CLL. The committee was to be provided with clinical data and determine the level of response and when progression occurred according to NCIWG guidelines. CT scans were not included in the response determinations. An independent radiology review was conducted by an independent imaging core laboratory (ICON medical imaging). A single board certified radiologist reviewed all imaging data to (1) confirm complete remissions and (2) verify the presence of bulky lymphadenopathy at study entry.
The protocol specified criteria for determination of ORR (complete plus partial responses) were based on the 1996 NCIWG guidelines [7] . The criteria for a partial The planned study sample size of 100 patients per treatment subgroup (DR and BFR) was based on the assumption of 30% ORR in the DR subgroup and the probability that the exact 2-sided 99% confidence interval would exclude a response rate of less than 15% with 63% power based on 66 patients in the interim analysis and 92% power based on 100 patients in the final analysis.
Results:
Efficacy: The initial activity-estimating trial, Hx-CD20-402 trial, evaluated 27 patients at the highest dose cohort. There was a 42% partial response rate with a median duration of response of 16 weeks across the entire study (n=33). There were one response reported in the 500 mg (n=3) cohort, none in the 1,000 mg (n=3) cohort, and 13 responses among the 27 patients enrolled at the 2,000mg dose cohort. Due to the relatively modest duration of responses observed with 4 weekly doses, the duration of treatment was increased in the Hx-CD20-406 trial.
The Hx-CD20-406 trial enrolled 154 patients at the time of the planned interim analysis.
The IRC conducted an audit of patient records and case report forms to confirm investigator-assigned patient subgroup classification; the IRC review identified 59 patients as double refractory (DR), 79 patients as bulky fludarabine refractory (BFR), and 16 patients as "other." This review will focus on the efficacy results from the IRCconfirmed DR group, the patient population that satisfied the regulatory definition of unmet medical need.
The overall population in study Hx-CD20-406 was heavily pretreated. In the DR group (n=59), the median number of prior therapies was 5 and the range was 1 to 14. Two patients in the DR group received one prior therapy; both of these patients received fludarabine combined with alemtuzumab. Baseline characteristics and prior treatment history are summarized for the DR subgroup and for the overall study population in Tables 1 and 2 , respectively. Nearly all (97%) patients enrolled in study Hx-CD20-406
were White and most were men (72%). Median time in years from original diagnosis to enrollment into study Hx-CD20-406 was 6.3 years. ZAP70 was not assessed at baseline.
Approximately one-quarter (26%) of the study population was accrued from U.S. sites. Table 2 shows that nearly all patients in the DR group, as well as the overall study population, received an alkylating agent-containing regimen. Over 50% of the patients in Study Hx-CD20-406 received prior rituximab; however, data were not collected to determine whether these patients were rituximab-refractory.
The magnitude of the treatment effect on ORR, as determined by the individual IRC members, IRC consensus determination, investigators, and FDA, differed. The ORR and DOR determined by the investigator, the IRC consensus finding, and FDA are summarized in Table 3 . The estimated DOR of response in the DR population was 6.5 months.
Unexpected findings in this trial were the high rate of discordance in tumor response assessment between the individual IRC members and the higher objective response rate as determined by the IRC as compared to that determined by the investigators.
Investigator assessments from study Hx-CD20-406 were derived from assessments of 
Safety Results:
Study Hx-CD20-406 was the only study submitted to the BLA that evaluated ofatumumab at the recommended doses and schedule. Because the data primarily were derived from an uncontrolled study, only a descriptive analysis of safety could be performed. In study Hx-CD20-406, 90% of patients received at least 8 infusions of ofatumumab and 55% received 12 infusions. The most common reasons for stopping treatment was disease progression and adverse reactions, mostly due to infections.
The most common adverse reactions (≥ 10%) in study Hx-CD20-406 were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections. Table 4 shows adverse reactions (ARs) that occurred in ≥ 5% of the total study population. The incidence of neutropenia as an AR is not described in the table because the laboratory data gave a more accurate description of neutropenia occurring after ofatumumab treatment.
Infusion reactions including sequelae of such reactions occurred frequently during the ofatumumab development program (all oncology and non-oncology studies). Infusion reactions were less common after the first two infusions. Serious infusion related reactions or sequelae included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac ischemia/infarction, back pain, abdominal pain, pyrexia, rash, urticaria, and angioedema. In a separate study of patients with moderate to severe chronic obstructive pulmonary disease, two of five patients developed Grade 3 bronchospasm during an infusion. In study HxCD20-406, infusion reactions occurred in 44% of patients on the day of the first infusion (300 mg), and 29% on the day of the second infusion (2,000 mg).
Infections frequently occurred after treatment with ofatumumab. In study Hx-CD20-406, 70% of patients experienced bacterial, viral, or fungal infections. A total of 29% of the study population experienced ≥ Grade 3 infections, of which 12% were fatal. The proportion of fatal infections in the DR group was 17%. One patient with CLL died of progressive multifocal leukoencephalopathy after receiving ofatumumab treatment in study Hx-CD20-406. One patient with rheumatoid arthritis died of fulminant hepatitis B infection after receiving ofatumumab in a non-oncology study.
Neutropenia frequently occurred or was exacerbated following ofatumumab treatment.
Of 108 patients with normal baseline neutrophil counts at baseline, 42% developed Grade 3 or greater neutropenia. Nineteen (18%) developed Grade 4 neutropenia. Some patients experienced new onset Grade 4 neutropenia for more than 2 weeks in duration.
Discussion:
FDA granted Subpart E (accelerated) approval under 21 CFR 601.41 for ofatumumab on October 26, 2009. Accelerated approval may be granted only for a drug that treats a serious or life-threatening illness and provides meaningful therapeutic benefit to patients over existing treatments (i.e., fulfills an unmet medical need), based upon demonstration of an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit.
FDA concluded that the subpopulation of patients studied in Hx-CD20-406 who were refractory to fludarabine and alemtuzumab, more than 90% of whom also received prior therapy that included an alkylating agent and who received a median of five prior treatments prior to enrollment in the Hx-CD20-406 study, was a patient population with FDA utilized the investigator-determined ORR and DOR for regulatory decision making.
FDA elected not to use the IRC determination for several reasons, including the high rate of disagreement across reviewers, the lack of direct evaluation of tumor measurements based on lack of serial radiographs for independent analysis, and the relatively minor contribution of hematologic laboratory data to the determination of ORR, and FDA's independent review of the case reports forms and supporting laboratory data.
The magnitude of the objective response rate in study Hx-CD20-406 could not be reproduced by multiple groups (investigators, IRC members, and FDA) given the same set of information. This lack of consistency appeared to be due to variability in interpretation and application of the 1996 NCIWG criteria for response assessments. In order to have consistent application, tumor response criteria should ideally be unambiguous such that given the same data, similar conclusions will be drawn by all response assessors. Such consistent application of the response criteria was not observed during the review of study Hx-CD20-406. Criteria that allow for such variability in interpretation are generally appropriate for the overall practice of medicine; however, the evidentiary standard required for regulatory decision-making is generally higher than those employed for clinical decision-making or for informing the overall practice of medicine.
Since the Hx-CD20-406 study was started, the NCIWG published new (2008) criteria that now recommend the use of CT scans in the response assessments of patients with CLL for clinical trials [9] . Based on these revised criteria and advice from the In hematologic malignancies, the clinical significance of a delay in disease progression is clearer since progression is generally associated with increased transfusion requirements and increased risk of infections. In patients with indolent hematologic malignancies, where median survival is measured in years, demonstration of effects on overall survival may not be a practical as an approval endpoint; however, evidence that there are no apparent detrimental effects on survival is generally required as an assessment of product safety.
Enrollment of the confirmatory GSK trial will be limited to patients deemed inappropriate for fludarabine-based treatment. In addition to confirming the clinical benefit of ofatumumab, a randomized confirmatory trial will allow for a more accurate characterization of adverse reactions caused by ofatumumab. Characterization of infections was especially problematic because the background rate of severe and fatal infections in heavily treated CLL patients is high [10] . Because of the high background rate of infections in this patient population and the absence of an internal control, it was not possible to determine the additional risk of infection posed by the administration of ofatumumab. However, ofatumumab-induced neutropenia may increase the risk of lifethreatening infections in this patient population. 
